Fulcrum Therapeutics (FULC) Profit After Tax: 2020-2025
Historic Profit After Tax for Fulcrum Therapeutics (FULC) over the last 5 years, with Sep 2025 value amounting to -$19.6 million.
- Fulcrum Therapeutics' Profit After Tax rose 9.68% to -$19.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$75.5 million, marking a year-over-year decrease of 321.56%. This contributed to the annual value of -$9.7 million for FY2024, which is 90.01% up from last year.
- As of Q3 2025, Fulcrum Therapeutics' Profit After Tax stood at -$19.6 million, which was down 10.99% from -$17.7 million recorded in Q2 2025.
- Fulcrum Therapeutics' 5-year Profit After Tax high stood at $55.4 million for Q2 2024, and its period low was -$34.1 million during Q2 2022.
- Its 3-year average for Profit After Tax is -$14.4 million, with a median of -$22.7 million in 2023.
- In the last 5 years, Fulcrum Therapeutics' Profit After Tax soared by 332.98% in 2024 and then tumbled by 131.86% in 2025.
- Over the past 5 years, Fulcrum Therapeutics' Profit After Tax (Quarterly) stood at -$23.5 million in 2021, then dropped by 11.29% to -$26.1 million in 2022, then increased by 5.28% to -$24.8 million in 2023, then surged by 33.07% to -$16.6 million in 2024, then rose by 9.68% to -$19.6 million in 2025.
- Its last three reported values are -$19.6 million in Q3 2025, -$17.7 million for Q2 2025, and -$16.6 million during Q4 2024.